Open in interactive viewer → charts, metric popovers & call review

MDxHealth: The 18-Quarter Streak Ends in a Hiring Problem

Flat revenue, a rebuilt sales force, $31.7 million of cash, and a $13.4 million market cap — the arithmetic of the next six months is now the whole story
MDXH · Earnings Call · 2026-11-12

MDxHealth: The 18-Quarter Streak Ends in a Hiring Problem

For four years Michael McGarrity sold one idea above all others: that MDxHealth was a forecastable 20% grower. On 2026-11-12 that idea died. Third-quarter revenue from continuing operations came in at $22.7 million — flat year over year. Gross margin slid 3.2 points to 61.8%. Operating loss nearly doubled to $8.1 million, net loss rose 26% to $12.3 million, and adjusted EBITDA swung from minus $0.9 million to minus $6.3 million. There is no guidance for Q4, none for 2027, and by the CEO's own admission the next two quarters are the floor: “we would expect that we've hit Q3 and Q4 running about in line with each other... that's the nadir, and the recovery begins in Q1, Q2, Q3, Q4 of next year.” — Michael McGarrity, Chief Executive Officer · 2026-11-12

Run a $22–23 million quarterly figure forward and the annualized business is roughly $91 million — against a February 2026 guide of $137–140 million and an August guide of $110–115 million. Two cuts in three quarters, then the guide itself was withdrawn. The cause, per management, is embarrassingly simple: reps left. “our Q3 results reflected temporary disruption in our commercial execution, driven by accelerated turnover within our sales organization following the discontinuation of Resolve, which was catalyzed by aggressive targeting from outside recruiters.” — Michael McGarrity, Chief Executive Officer · 2026-11-12 The company eliminated the Chief Commercial Officer role and split sales and marketing into two groups reporting directly to the CEO. The top keyword for the quarter — and the highest-momentum term in this company's entire mover history — is commercial organization, with commercial reset close behind and considerable progress in backfilling and retention filling out the slate. That is not a product story. It is an org-chart story, and org-chart stories are what companies talk about when the P&L has stopped cooperating.

The Keyword Trail: What Management Stopped Saying

The most telling thing in this report is the silence. In the prior three quarters, the company's keyword slate was a clinical and strategic narrative: ProtecT and ProMPT both spiked as high-momentum themes in Q3 2026 alongside AI initiative, active surveillance population, ProMPT data, and the ExoDx integration. This quarter, none of those crack the top-30 except a surviving strategic AI initiatives mention. What replaced them is a vocabulary of internal repair: caliber of talent, administrative teams, client service group, direct visibility, and — most damningly — forecast accuracy, the very quality the company just lost.

Note also the substitution at the top of the vocabulary. sales force and sales organization were top-of-book keywords through 2025 and into 2026, repeatedly framed as a source of pride and execution. They now appear mostly as something under construction. McGarrity's aspiration is unchanged in language — “our goal ultimately is to get back what we had demonstrated for 18 quarters in a row, which is 20% top-line growth” — Michael McGarrity, Chief Executive Officer · 2026-11-12 — but the mechanism is now process theatre: rigorous selection, a "rule of threes" on performance tiers, and a confident assertion that the hiring bar has not slipped: “I would say we've virtually cleared that step one hurdle based on the work of the sales managers.” — Michael McGarrity, Chief Executive Officer · 2026-11-12

And then the denial that anything structural was amiss: “It's not like it was broken, but we think it's time.” — Michael McGarrity, Chief Executive Officer · 2026-11-12 Which is odd, because a quarter of flat revenue and a tripled EBITDA loss is generally what broken looks like.

The third part of your question of what's coming, it's clear our relationship with Exact and Abbott and our debt facility with OrbiMed, I would just comment that those are our two long-term partners... If you made the assumption that we expect that to continue as we navigate through this difficulty, candidly, yes, we do.

Michael McGarrity, Chief Executive Officer · 2026-11-12

Cash, Partners, and the ProtecT Alibi

That OrbiMed answer is the real disclosure of the call. Bill Bonello asked directly about cash burn and the analyst's framing was blunt — it's "sort of all about cash." Cash stood at $31.7 million at September 30 against a negative $6.3 million quarterly adjusted EBITDA and a restructuring still in flight. That is perhaps four to five quarters of runway before dilution or renegotiation, and the company chose to answer in code words about "partners" rather than with a number. A debt facility with OrbiMed now appears as a named keyword for the first time in this company's curated history, sitting alongside a recurring cash outlay theme that surfaced back in Q2 2026 and never fully got resolved.

The market has already voted on this arithmetic. MDxHealth's entire market capitalization is $13.4 million — roughly 42% of the cash on the balance sheet. Equity here is being valued as an option on the ProtecT readout, not as a claim on a $91 million annualized revenue stream. That reframes the entire call: the AI partnership work, the Oxford collaboration, and the peer-reviewed ProMPT data are all deferred to "the first half of 2027" and to what management calls a catalyst-rich period in 2027 — while the business that funds the wait is shrinking. McGarrity was explicit that the AI thread is real but not yet visible: “we expect that to begin to show evidence in the first half of 2027.” — Michael McGarrity, Chief Executive Officer · 2026-11-12

The Guideline Question Nobody Wants to Answer

The other quiet thread is guideline changes, which reaches rank three this quarter despite management's insistence it is a non-event. Two separate analysts probed whether NCCN revisions around the low-risk population hit demand; McGarrity's answer was that the changes went back several iterations and had no material effect, dismissing a lot of what he called "misinformation": “I don't know that I would pin anything on our performance specifically related to any guidelines change, whether our positive performance or the difficulty that we're navigating through right now.” — Michael McGarrity, Chief Executive Officer · 2026-11-12 Perhaps. But this is a company whose GPS test sells at a $3,850 Medicare ASP into the active-surveillance niche while a competitor dominates the high-risk space, and whose revenue just went flat. The bear reading is that some portion of the Q3 shortfall is competitive rather than clerical — and the company cannot yet distinguish the two, because its own sales reporting infrastructure was the thing that broke.

What would make this a buy? A Q4 print at or above $23 million, evidence that the sales force is genuinely full by year-end, and any ProtecT timeline management will actually commit to. What we got instead was a promise of guidance "at the beginning of the year" for a business that was, nine months ago, guiding to $140 million. The streak of 18 quarters is over. The question now is whether MDxHealth is a temporarily distracted 20% grower or a sub-$100 million diagnostics company with a debt partner and a shrinking equity cushion — and this call did not answer it.